Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857

IDH1 and IDH2 Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163

Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

Sanson, M., Marie, Y., Paris, S., Idbaïh, A., Laffaire, J., Ducray, F., Hallani, S. E., Boisselier, B., Mokhtari, K., Hoang‐Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,049

Analysis of the IDH1 codon 132 mutation in brain tumors

Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027

Chaperone Coexpression Plasmids: Differential and Synergistic Roles of DnaK-DnaJ-GrpE and GroEL-GroES in Assisting Folding of an Allergen of Japanese Cedar Pollen, Cryj2, in Escherichia coli

Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., & Yura, T. (1998) · Applied and Environmental Microbiology · doi:10.1128/aem.64.5.1694-1699.1998 · Cited by 440

Cancer-Associated Isocitrate Dehydrogenase Mutations

Yen, K. E., & Schenkein, D. P. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0429 · Cited by 21

Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance

Lachowiez, C. A., Dinardo, C. D., & Loghavi, S. (2023) · Cancers · doi:10.3390/cancers15051617 · Cited by 20

Epigenetic deregulation in myeloid malignancies

Huang, H.-T., & Figueroa, M. E. (2021) · Blood · doi:10.1182/blood.2019004262 · Cited by 21

D-2-hydroxyglutarate dehydrogenase governs adult neural stem cell activation and promotes histone acetylation via ATP-citrate lyase

Liu, Y., Wang, M., Guo, Y., Wang, L., & Guo, W. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112067 · Cited by 21

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 22

Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice

Mylonas, E., Janin, M., Bawa, O., Opolon, P., David, M. D., Quivoron, C., Bernard, O., Ottolenghi, C., Debotton, S., & Penard‐Lacronique, V. (2014) · Leukemia · doi:10.1038/leu.2014.18 · Cited by 20

Complex role of HIF in cancer: the known, the unknown, and the unexpected

Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 20

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Lu, X., Han, L., Busquets, J., Collins, M., Lodi, A., Marszalek, J. R., Konopleva, M. Y., & Tiziani, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686765 · Cited by 20

Altered metabolite levels and correlations in patients with colorectal cancer and polyps detected using seemingly unrelated regression analysis

Chen, C., Gowda, G. A. N., Zhu, J., Deng, L., Gu, H., Chiorean, E. G., Zaid, M. I. A., Harrison, M. L., Zhang, D., Zhang, M., et al. (2017) · Metabolomics · doi:10.1007/s11306-017-1265-0 · Cited by 20

Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

Lin, P., Luo, Y., Zhu, S., Maggio, D. M., Yang, H., Hu, C., Wang, J., Zhang, H., Ren, Y., Zhou, X., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2627-3 · Cited by 20

Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

Mellinghoff, I. K., Chang, S. M., Jaeckle, K. A., & van den Bent, M. J. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.008 · Cited by 21

The Interplay between Dysregulated Metabolism and Epigenetics in Cancer

Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19

Zebrafish models of leukemia

He, S., Jing, C., & Look, A. T. (2017) · Methods in cell biology · doi:10.1016/bs.mcb.2016.11.013 · Cited by 20

IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells

Kim, G., Choi, S. Y., Oh, T.-I., Kan, S.-Y., Kang, H., Lee, S., Oh, T., Ko, H. M., & Lim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112679 · Cited by 19

Potential mechanisms linking SIRT activity and hypoxic 2-hydroxyglutarate generation: no role for direct enzyme (de)acetylation

Nadtochiy, S. M., Wang, Y. T., Zhang, J., Nehrke, K. W., Schafer, X., Welle, K. A., Ghaemmaghami, S., Munger, J., & Brookes, P. S. (2017) · Biochemical Journal · doi:10.1042/bcj20170389 · Cited by 19

Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells

Chen, J., Yang, J., Wei, Q., Weng, L., Wu, F., Shi, Y. Y., Cheng, X., Cai, X., Hu, C., & Cao, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00536-7 · Cited by 19

Interaction between transforming Theileria parasites and their host bovine leukocytes

Tajeri, S., Haidar, M., Sakura, T., & Langsley, G. (2021) · Molecular Microbiology · doi:10.1111/mmi.14642 · Cited by 19

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Showalter, M. R., Hatakeyama, J., Čajka, T., VanderVorst, K., Carraway, K. L., Fiehn, O., & Reproducibility Project: Cancer Biology (2017) · eLife · doi:10.7554/elife.26030 · Cited by 19

DNMT3AR882H accelerates angioimmunoblastic T-cell lymphoma in mice

Zheng, J., Wang, Z., Pan, X., Zhang, Z., Li, H., Deng, X., Liu, P., Zhang, Q., Na, F., Chen, C., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02699-2 · Cited by 20

Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

Stein, E. M., & Yen, K. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122051 · Cited by 18

D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation

Li, T., Cox, C. D., Ozer, B. H., Nguyen, N. T., Nguyen, H. N., Lai, T. J., Li, S., Liu, F., Kornblum, H. I., Liau, L. M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0367 · Cited by 18

Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies

Zhang, M., Yin, J., He, Q., Zhang, F., Huang, H., Wu, B., Wang, X., Liu, H., Yin, H., Zeng, Y., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.04.009 · Cited by 18

Biphasic Papillary and Lobular Breast Carcinoma With PIK3CA and IDH1 Mutations

Ang, D. C., VanSandt, A. M., Beadling, C., Warrick, A., West, R. B., Corless, C. L., & Troxell, M. L. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31826ddbd1 · Cited by 19

Modeling Myeloid Malignancies Using Zebrafish

Potts, K. S., & Bowman, T. V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00297 · Cited by 18

A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres

Borodovsky, A., Meeker, A. K., Kirkness, E. F., Zhao, Q., Eberhart, C. G., Gallia, G. L., & Riggins, G. J. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1672-2 · Cited by 18

Understanding and Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: An Updated Comprehensive Review

Addanki, S., Kim, L. E., & Stevens, A. M. (2025) · Cancers · doi:10.3390/cancers17081355 · Cited by 18

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

Khalil, A. F., El-Moselhy, T. F., El-Bastawissy, E. A., Abdelhady, R., Younis, N. S., & El‐Hamamsy, M. H. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2157411 · Cited by 17

Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?

Trovarelli, G., Sbaraglia, M., Angelini, A., Bellan, E., Pala, E., Belluzzi, E., Pozzuoli, A., Borga, C., Tos, A. P. D., & Ruggieri, P. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000002960 · Cited by 17

Diagnostic markers for glioblastoma.

Jung, C. S., Unterberg, A. W., & Hartmann, C. J. (2011) · PubMed · doi:10.14670/hh-26.1327 · Cited by 17

Epigenetic targeting and personalized approaches for AML

Roboz, G. J. (2014) · Hematology · doi:10.1182/asheducation-2014.1.44 · Cited by 17

Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7

Wu, D. (2015) · Tumor Biology · doi:10.1007/s13277-015-4358-2 · Cited by 17

Tissue metabolic profiling of lymph node metastasis of colorectal cancer assessed by 1H NMR

Zhang, H., Qiao, L., Li, X., Wan, Y., Yang, L., & Wang, H. (2016) · Oncology Reports · doi:10.3892/or.2016.5175 · Cited by 17

Metabolomic comparison between cells over‐expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism

Wen, H., Cho, H. R., Yun, T., Kim, H., Park, C., Lee, S., Choi, S. H., & Park, S. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12950 · Cited by 20

Molecular biology of Philadelphia-negative myeloproliferative neoplasms

Campregher, P. V., Santos, F. P. D. S., Perini, G. F., & Hamerschlak, N. (2012) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20120035 · Cited by 18

Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening

Duan, Z., Liu, J., Niu, L., Wang, J., Feng, M., Chen, H., & Luo, C. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.040 · Cited by 17

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia

Cortes, J. E. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2354486 · Cited by 16

Multi-study Integration of Brain Cancer Transcriptomes Reveals Organ-Level Molecular Signatures

Sung, J., Kim, P., Ma, S., Funk, C. C., Magis, A. T., Wang, Y., Hood, L., Geman, D., & Price, N. D. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003148 · Cited by 16

Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer

Tang, J., Chang, C., Lin, P., & Chang, J. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2011.10.023 · Cited by 16

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer

Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 16

Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors

Liu, X., Hu, Y., Gao, A., Xu, M., Gao, L., Xu, L., Zhou, Y., Gao, J., Ye, Q., & Li, J. X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.12.029 · Cited by 16

Molecular Classification of Diffuse Gliomas

Kalidindi, N., Or, R., Babak, S., & Mason, W. P. (2020) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2020.10 · Cited by 16

The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis

Hindilerden, İ. Y., Aday, A. D., Hindilerden, F., Akadam-Teker, B., Yılmaz, C., Nalçacı, M., Yavuz, A. S., & Sargın, D. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2405w · Cited by 16

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D‐2‐hydroxyglutaric aciduria type II mouse model

Wang, F., Travins, J. M., Lin, Z., Si, Y., Chen, Y., Powe, J., Murray, S., Zhu, D., Artin, E., Größ, S., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9960-y · Cited by 16

Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

Tong, Z., Atsriku, C., Yerramilli, U., Wang, X., Li, Y., Reyes, J. F., Fan, B., Yang, H. Q., Hoffmann, M., & Surapaneni, S. (2018) · Xenobiotica · doi:10.1080/00498254.2018.1425511 · Cited by 16

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic LiabilityPreprint

Gunn, K., & Losman, J.-A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041537 · Cited by 16

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

Perner, F., Berg, T., Sasca, D., Mersiowsky, S., Gadrey, J. Y., Thomas, J. M., Kühn, M. W. M., & Lübbert, M. (2025) · International Journal of Cancer · doi:10.1002/ijc.35389 · Cited by 16

Emerging biological therapies for the treatment of myelodysplastic syndromes

Zeidan, A. M., Stahl, M. F., & Komrokji, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220534 · Cited by 15

The Biology and Management of Cartilaginous Tumors: A Role For Targeting Isocitrate Dehydrogenase

Tinoco, G., Wilky, B. A., Paz-Mejia, A. C., Rosenberg, A. E., & Trent, J. C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e648 · Cited by 15

Recent Discoveries in Molecular Characterization of Acute Myeloid Leukemia

Khasawneh, M. K., & Abdel-Wahab, O. I. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0200-y · Cited by 15

Metabolic alteration in tumorigenesis

Yang, H., Xiong, Y., & Guan, K. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4549-2 · Cited by 16

Isocitrate Dehydrogenase from Streptococcus mutans: Biochemical Properties and Evaluation of a Putative Phosphorylation Site at Ser102

Wang, P., Song, P., Jin, M., & Zhu, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058918 · Cited by 15

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

de Botton, S., Brandwein, J. M., Wei, A. H., Pigneux, A., Quesnel, B., Thomas, X., Legrand, O., Récher, C., Chantepie, S., Hunault, M., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4182 · Cited by 15

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing

Easwar, A., & Siddon, A. J. (2021) · Life · doi:10.3390/life11111158 · Cited by 15

Highlighting the mechanistic role of Olutasidenib (FT-2102) in the selective inhibition of mutated isocitrate dehydrogenase 1 (mIDH1) in cancer therapy

Salifu, E. Y., Agoni, C., & Soliman, M. E. S. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100829 · Cited by 15

Genetic, metabolic and immunological features of cancers with NRF2 addiction

Kitamura, H., Takeda, H., & Motohashi, H. (2022) · FEBS Letters · doi:10.1002/1873-3468.14458 · Cited by 15

Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting

Ibáñez, M., Such, E., Cervera, J., Luna, I., Gómez‐Seguí, I., López‐Pavía, M., Dolz, S., Barragán, E., Fuster, Ó., Llop, M., et al. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.06.006 · Cited by 15

Novel Therapeutics in Acute Myeloid Leukemia

Dinardo, C. D., Stone, R. M., & Medeiros, B. C. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175401 · Cited by 15

Synthesis of [1‐13C‐5‐12C]‐alpha‐ketoglutarate enables noninvasive detection of 2‐hydroxyglutarate

Miura, N., Mushti, C., Sail, D., AbuSalim, J. E., Yamamoto, K., Brender, J., Seki, T., AbuSalim, D. I., Matsumoto, S., Camphausen, K. A., et al. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4588 · Cited by 15

Differentiation Therapy

Chen, S., Yan, X., Zhou, G., & Chen, Z. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011 · Cited by 15

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Lee, C. L., O'Kane, G. M., Mason, W. P., Zhang, W.-J., Spiliopoulou, P., Hansen, A. R., Grant, R. C., Knox, J. J., Stockley, T. L., Zadeh, G. M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0460 · Cited by 14

Advances in Understanding the Coupling of DNA Base Modifying Enzymes to Processes Involving Base Excision Repair

Wyatt, M. D. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00002-2 · Cited by 14

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation

Kato, Y., & Kaneko, M. K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.106 · Cited by 14

2‐Hydoxyglutarate: D/Riving Pathology in gLiomaS

Wahl, D. R., & Venneti, S. (2015) · Brain Pathology · doi:10.1111/bpa.12309 · Cited by 14

Perturbations of 5-Hydroxymethylcytosine Patterning in Hematologic Malignancies

Madžo, J., Vasanthakumar, A., & Godley, L. A. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.01.004 · Cited by 14

IDH1 fine-tunes cap-dependent translation initiation

Liu, L., Lu, J. Y., Li, F., Xing, X., Li, T., Yang, X., & Shen, X. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz082 · Cited by 14

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells

Kim, Y., Jeung, H.-K., Cheong, J., Song, J., Bae, S. H., Lee, J. I., & Min, Y. H. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.9.762 · Cited by 16

The dominant TP53 hotspot mutation in IDH -mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications

Marker, D. F., Agnihotri, S., Amankulor, N., MURDOCH, G. H., & Pearce, T. M. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab182 · Cited by 14

Maternal high-fat diet changes DNA methylation in the early embryo by disrupting the TCA cycle intermediary alpha ketoglutarate

Penn, A., McPherson, N. O., Fullston, T., Arman, B. M., & Zander‐Fox, D. (2023) · Reproduction · doi:10.1530/rep-22-0302 · Cited by 14

Structure and biochemical characterization of l-2-hydroxyglutarate dehydrogenase and its role in the pathogenesis of l-2-hydroxyglutaric aciduria

Yang, J., Chen, X., Jin, S., & Ding, J. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105491 · Cited by 14

Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening

Zou, F., Pusch, S., Eisel, J., Ma, T., Zhu, Q., Deng, D., Gu, Y., Xu, Y., von Deimling, A., & Zha, X. (2016) · RSC Advances · doi:10.1039/c6ra21617j · Cited by 14

Background Levels of Neomorphic 2-hydroxyglutarate Facilitate Proliferation of Primary Fibroblasts

Dvořák, A., Zelenka, J., Smolková, K., Vı́tek, L., & Ježek, P. (2017) · Physiological Research · doi:10.33549/physiolres.933249 · Cited by 14

Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate

Dexter, J. P., Ward, P. S., Dasgupta, T., Hosios, A. M., Gunawardena, J., & Heiden, M. G. V. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004278 · Cited by 14

2-Hydroxyglutarate Metabolism Is Altered in an in vivo Model of LPS Induced Endotoxemia

Fitzpatrick, S. F., Lambden, S., Macías, D., Puthucheary, Z., Pietsch, S., Mendil, L., McPhail, M. J. W., & Johnson, R. S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00147 · Cited by 14

Metabolism of glioma and IDH1/IDH2 mutations

Rossetto, M., Ciccarino, P., Boisselier, B., Labussière, M., & Sanson, M. (2011) · Revue Neurologique · doi:10.1016/j.neurol.2011.08.002 · Cited by 14

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing

Kirschner, M., Schemionek, M., Schubert, C., Chatain, N., Sontag, S., Isfort, S., Ortiz‐Brüchle, N., Schmitt, K., Krüger, L., Zerres, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123476 · Cited by 14

Put in a “Ca2+ll” to Acute Myeloid Leukemia

Lewuillon, C., Laguillaumie, M.-O., Quesnel, B., Idziorek, T., Touil, Y. S., & Lemonnier, L. (2022) · Cells · doi:10.3390/cells11030543 · Cited by 16

Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation

Sahm, F., Capper, D., Meyer, J., Hartmann, C. J., Herpel, E., Andrulis, M., Mechtersheimer, G., Petersen, I., Paulus, W., & von Deimling, A. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03823.x · Cited by 13

Synthesis of the 1-Monoester of 2-Ketoalkanedioic Acids, for Example, Octyl α-Ketoglutarate

Jung, M. E., & Deng, G. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo302308q · Cited by 13

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects

Li, Y., Liu, L., Gomez, D., Chen, J., Tong, Z., Palmisano, M., & Zhou, S. Y. (2018) · Pharmacology Research & Perspectives · doi:10.1002/prp2.436 · Cited by 13

Quantitation of 2-Hydroxyglutarate in Human Plasma Via LC–MS/MS Using a Surrogate Analyte Approach

Yin, F. Q., Ling, Y., Keller, J., Kraus, D. H., Narayanaswamy, R., Mangus, H., Li, F., Yang, H. Q., & Liu, G. (2020) · Bioanalysis · doi:10.4155/bio-2020-0131 · Cited by 13

Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas

Zheng, P., van der Weiden, M., van der Spek, P. J., Vincent, A. J. P. E., & Kros, J. M. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20836 · Cited by 13

Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations

Fernández‐Galán, E., Massana, N., Parra‐Robert, M., Hidalgo, S., Casals, G., Esteve, J., & Jiménez, W. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.02.038 · Cited by 13

The Distribution and Significance of IDH Mutations in Gliomas

Mellai, M., Caldera, V., Annovazzi, L., & Schiffer, D. (2013) · InTech eBooks · doi:10.5772/52357 · Cited by 14

Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy

Bret, C., Viziteu, E., Kassambara, A., & Moreaux, J. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1141673 · Cited by 13

Something Old and Something New About Molecular Diagnostics in Gliomas

Horbinski, C. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.09.001 · Cited by 13

Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort

Cortes, J., Curti, A., Fenaux, P., Jonas, B. A., Krauter, J., Montesinos, P., Récher, C., Taussig, D. C., Wang, E. S., Watts, J. M., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01751-w · Cited by 12

Quantitative detection ofIDH2mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations inNPM1gene

Ježíšková, I., Rázga, F., Tošková, M., Dvořáková, D., Timilsina, S., Mayer, J., & Ráčil, Z. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.727414 · Cited by 12

Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC–MS/MS

Pang, N.-H., Liu, Q., Lu, X.-R., Yang, S.-F., Lin, D., & Hu, G. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.04.039 · Cited by 12

Glucose restriction reverses the Warburg effect and modulates PKM2 and mTOR expression in breast cancer cell lines

Tahtouh, R., Wardi, L., Sarkis, R., Hachem, R. Y., RAAD, I. I., Zein, N. E., & Hilal, G. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.7.6 · Cited by 12

Metabolic Hijacking of Hexose Metabolism to Ascorbate Synthesis Is the Unifying Biochemical Basis of Murine Liver Fibrosis

Beyoğlu, D., Huang, P., Skelton-Badlani, D., Zong, C., Popov, Y. V., & Idle, J. R. (2023) · Cells · doi:10.3390/cells12030485 · Cited by 12

Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells

Worth, A. J., Gillespie, K. P., Mesaros, C., Guo, L., Basu, S. S., Snyder, N. W., & Blair, I. A. (2015) · Chemical Research in Toxicology · doi:10.1021/tx500535c · Cited by 12

Epigenetics and blood disorders

Scholz, B., & Marschalek, R. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09193.x · Cited by 13

Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase

Yamamoto, M., Tanaka, H., Toki, Y., Hatayama, M., Ito, S., Addo, L., Shindo, M., Sasaki, K., Ikuta, K., Ohtake, T., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2054-7 · Cited by 12

Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy

Li, L., Eid, J. E., Paz, A. C., & Trent, J. C. (2017) · BioDrugs · doi:10.1007/s40259-017-0237-2 · Cited by 12

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis

Tiburcio, P. D. B., Xiao, B., Berg, S., Asper, S., Lyne, S. B., Zhang, Y., Zhu, X., Yan, H., & Huang, L. E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1800-0 · Cited by 12

Enchondromatosis and Growth Plate Development

Zhang, H., & Alman, B. A. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00639-7 · Cited by 12

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia

Lachowiez, C., DiNardo, C. D., & Stein, E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000570 · Cited by 12

New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein

Kaelin, W. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05781.x · Cited by 12

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique

Voelxen, N., Walenta, S., Proescholdt, M. A., Dettmer, K., Pusch, S., & Mueller‐Klieser, W. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00046 · Cited by 12

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

Gruber, E., & Kats, L. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20230017 · Cited by 11

Abstract 5452: Cancer-associated metabolite 2-hydroxyglutarate accumulates in AML with IDH1/2 mutations

Fantin, V. R., Größ, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S.-S. M., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-5452 · Cited by 1

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020

Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Fantin, V. R., Dang, L., White, D. W., Größ, S., Bittinger, M. A., Driggers, E. M., Jang, H. G., Jin, S., Keenan, M. C., Marks, K. M., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-33 · Cited by 5

IDH mutations in glioma and acute myeloid leukemia

Dang, L., Jin, S., & Su, S.-S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 384

Abstract 1369 Modeling Isocitrate Dehydrogenase 2 Mutations in Acute Myeloid Leukemia: Exploring how the drug AG-221 Inhibits 2-hydroxyglutarate Production and Restores Blood Cell Differentiation

Matta, J., Bourke, B., Balani, B., Punjal, N., Dore, M., Lavin, E. S., & Sikora, A. K. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108578